TNFSF11 and Miyoshi myopathy: The classical bone-targeting agents bisphosphonates and Denosumab (anti-RANKL antibody) have been shown to decrease the incidence of skeletal-related events in patients with MM and in those with bone metastases (regardless of the tumour type), but they do not replace the missing bone and, therefore, patients remain at risk of developing fractures, while the use of bone anabolic agents is not yet approved for routine clinical practice (115).